Regulatory Expanded US Imaavy approval first ever for wAIHA PharmaphorumThe FDA has approved Johnson Johnson's Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA).HematologyRead full story pharminent August 25, 2026 (Last updated: August 26, 2026) Pharmaphorum The FDA has approved Johnson Johnson’s Imaavy (nipocalimab-aahu) for the treatment of warm autoimmune haemolytic anaemia (wAIHA). Hematology Read full story Post navigation Previous: Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage failNext: China’s Haisco forms immunology biotech with up to $1.5B from American VCs Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026